A DNA screening to look for fetal abnormalities can render some unexpected results. According to a new analysis, a cell-free ...

Learn how donor-derived cell-free DNA (dd-cfDNA) offers a minimally invasive, sensitive approach for early detection of graft ...

Discover how voided urine cfDNA emerges as a promising biomarker for upper tract urothelial carcinoma, offering a less ...

NIPT is an early blood test that screens for Down syndrome and other conditions – and it can tell you your baby's gender.

Many moms-to-be opt for blood tests during pregnancy to check for fetal disorders such as Down syndrome. In rare instances, ...

▲ 点击上方蓝字关注CellPress细胞科学 ▲生命科学Life science自人类基因组计划以来，科学家不断探索疾病、健康与长寿的遗传奥秘，逐步构建起以千人基因组计划、UK Biobank、TOPMed、All of ...

A new prenatal test offered accurate, noninvasive fetal RHD determination starting at nine weeks of pregnancy.

Early detection of fetal Rhesus D (RhD) status and possible hemolytic disease of the fetus and newborn (HDFN) via a noninvasive cell-free DNA (cfDNA) screening test has been adopted widely in ...

Many moms-to-be opt for blood tests during pregnancy to check for fetal disorders such as Down syndrome. In rare instances, these tests can reveal something unexpected — hints of a hidden cancer in ...

Almost half of pregnant or postpartum women with unusual or nonreportable clinical cell-free (cf)DNA-sequencing results have occult cancer.

Multicancer early detection testing results in extended life-years and reduced cancer treatment costs through earlier diagnosis, leading to a cost-effective option in cancer screening.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC ...